Cue Biopharma Net Income
| CUE Stock | USD 0.31 0.01 3.33% |
As of the 15th of February 2026, Cue Biopharma shows the risk adjusted performance of (0.07), and Mean Deviation of 5.6. Cue Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cue Biopharma market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Cue Biopharma is priced correctly, providing market reflects its regular price of 0.31 per share. As Cue Biopharma appears to be a penny stock we also recommend to validate its jensen alpha numbers.
Cue Biopharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 2.1981 | Revenue | Earnings Share (0.41) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -36.6 M | -38.4 M | |
| Net Loss | -47.7 M | -50.1 M | |
| Net Loss | -36.6 M | -38.4 M | |
| Net Loss | (0.83) | (0.87) | |
| Net Income Per E B T | 1.16 | 1.11 |
Cue | Net Income | Build AI portfolio with Cue Stock |
Analyzing Cue Biopharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Cue Biopharma's current valuation and future prospects.
Latest Cue Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Cue Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cue Biopharma financial statement analysis. It represents the amount of money remaining after all of Cue Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cue Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (40.67 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cue Net Income Regression Statistics
| Arithmetic Mean | (25,091,143) | |
| Coefficient Of Variation | (80.92) | |
| Mean Deviation | 18,619,370 | |
| Median | (36,606,600) | |
| Standard Deviation | 20,303,919 | |
| Sample Variance | 412.2T | |
| Range | 51.1M | |
| R-Value | (0.87) | |
| Mean Square Error | 105.6T | |
| R-Squared | 0.76 | |
| Slope | (3,505,009) | |
| Total Sum of Squares | 6596T |
Cue Net Income History
Other Fundumenentals of Cue Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cue Biopharma Net Income component correlations
Cue Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cue Biopharma is extremely important. It helps to project a fair market value of Cue Stock properly, considering its historical fundamentals such as Net Income. Since Cue Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cue Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cue Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Cue diversify its offerings? Factors like these will boost the valuation of Cue Biopharma. Projected growth potential of Cue fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cue Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
Cue Biopharma's market price often diverges from its book value, the accounting figure shown on Cue's balance sheet. Smart investors calculate Cue Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cue Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cue Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cue Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cue Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cue Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cue Biopharma.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Cue Biopharma on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Cue Biopharma or generate 0.0% return on investment in Cue Biopharma over 90 days. Cue Biopharma is related to or competes with NRX Pharmaceuticals, OUTLOOK THERAPEUTICS, Equillium, Coeptis Therapeutics, Spruce Biosciences, IO Biotech, and Century Therapeutics. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of... More
Cue Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cue Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cue Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 50.98 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 11.11 |
Cue Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cue Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cue Biopharma's standard deviation. In reality, there are many statistical measures that can use Cue Biopharma historical prices to predict the future Cue Biopharma's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.97) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.50) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 5.6 | |||
| Coefficient Of Variation | (973.37) | |||
| Standard Deviation | 8.33 | |||
| Variance | 69.38 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.97) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 50.98 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 11.11 | |||
| Skewness | 1.3 | |||
| Kurtosis | 5.07 |
Cue Biopharma Backtested Returns
Cue Biopharma secures Sharpe Ratio (or Efficiency) of -0.0754, which signifies that the company had a -0.0754 % return per unit of standard deviation over the last 3 months. Cue Biopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cue Biopharma's mean deviation of 5.6, and Risk Adjusted Performance of (0.07) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.72, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cue Biopharma will likely underperform. At this point, Cue Biopharma has a negative expected return of -0.64%. Please make sure to confirm Cue Biopharma's jensen alpha and the relationship between the value at risk and day typical price , to decide if Cue Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.45 |
Average predictability
Cue Biopharma has average predictability. Overlapping area represents the amount of predictability between Cue Biopharma time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cue Biopharma price movement. The serial correlation of 0.45 indicates that just about 45.0% of current Cue Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.45 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cue Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cue Biopharma reported net income of (40.67 Million). This is 111.92% lower than that of the Biotechnology sector and 158.07% lower than that of the Health Care industry. The net income for all United States stocks is 107.12% higher than that of the company.
Cue Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cue Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics of similar companies.Cue Biopharma is currently under evaluation in net income category among its peers.
Cue Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cue Biopharma from analyzing Cue Biopharma's financial statements. These drivers represent accounts that assess Cue Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cue Biopharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 353.8M | 101.6M | 120.8M | 61.4M | 70.6M | 67.1M | |
| Enterprise Value | 301.5M | 69.3M | 87.0M | 47.8M | 55.0M | 52.2M |
Cue Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Cue Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cue Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cue Biopharma's value.| Shares | Susquehanna International Group, Llp | 2025-06-30 | 154.2 K | Renaissance Technologies Corp | 2025-06-30 | 133.5 K | Northern Trust Corp | 2025-06-30 | 132.6 K | Chicago Partners Investment Group Llc | 2025-06-30 | 88.3 K | Northwestern Mutual Wealth Management Co | 2025-06-30 | 83 K | Lpl Financial Corp | 2025-06-30 | 59.4 K | Sigma Planning Corp | 2025-06-30 | 55.5 K | Texas Capital Bank Wealth Management Services Inc | 2025-06-30 | 33.1 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 29.5 K | Bleichroeder Lp | 2025-06-30 | 6.8 M | Catalytic Wealth Ria Llc | 2025-06-30 | 3.3 M |
Cue Fundamentals
| Return On Equity | -1.95 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (3.51) % | ||||
| Current Valuation | 15.61 M | ||||
| Shares Outstanding | 91.24 M | ||||
| Shares Owned By Insiders | 0.74 % | ||||
| Shares Owned By Institutions | 24.76 % | ||||
| Number Of Shares Shorted | 2.17 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 3.94 X | ||||
| Revenue | 9.29 M | ||||
| Gross Profit | (28.32 M) | ||||
| EBITDA | (37.53 M) | ||||
| Net Income | (40.67 M) | ||||
| Cash And Equivalents | 66.13 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 8.88 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 8.29 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (36.33 M) | ||||
| Short Ratio | 1.14 X | ||||
| Earnings Per Share | (0.41) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 41 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 27.97 M | ||||
| Total Asset | 32.19 M | ||||
| Retained Earnings | (341.86 M) | ||||
| Working Capital | 11.45 M | ||||
| Current Asset | 42.21 M | ||||
| Current Liabilities | 3.38 M | ||||
| Net Asset | 32.19 M |
About Cue Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cue Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cue Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cue Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Cue diversify its offerings? Factors like these will boost the valuation of Cue Biopharma. Projected growth potential of Cue fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cue Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
Cue Biopharma's market price often diverges from its book value, the accounting figure shown on Cue's balance sheet. Smart investors calculate Cue Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cue Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cue Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cue Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.